SLC5A2 and hydrops fetalis: In a real-world study from Denmark SGLT-2 inhibitor and GLP-1 receptor agonist combination resulted in lower five year rates of all-cause mortality, HF, end-stage kidney disease, and > 50% decline in eGFR compared to each individual drug class [30, 31].